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Melanoma frequently metastasizes to the central
nervous system (CNS). The diagnosis of CNS meta-
stases typically is made following the onset of
clinical symptoms. Thus, more sensitive diagnostic
approaches are needed to identify subclinical CNS
metastases. Currently, standard cytologic analysis of
the cerebrospinal ¯uid (CSF) is limited by its poor
sensitivity. A more sensitive assay was therefore
developed using multiple reverse transcriptase-poly-
merase chain reaction (RT-PCR) markers. CSF was
collected and assessed by RT-PCR for three known
melanoma-associated markers (MAGE-3, MART-1,
and tyrosinase) to detect occult metastatic melanoma
cells in the CSF of 37 American Joint Committee
on Cancer (AJCC) stage IV melanoma patients.
Cytologic analysis of CSF was performed on all
patients, and immunohistochemistry (IHC) analysis
was performed on 33 CSF samples using anti-S100
and anti-HMB-45 antibodies. Only one patient (3%)
had tumor-positive CSF cytology and IHC upon
entry into the study, whereas 12 patients (32%) were
positive for at least one RT-PCR marker. The
correlation between CSF RT-PCR positivity of
MART-1 and/or MAGE-3 and the development of
CNS metastases at 3 mo was signi®cant (p = 0.04).
Fifteen of 37 patients (41%) had either positive MRI
and/or positive RT-PCR results. Multimarker RT-
PCR is more informative and sensitive than cytol-
ogy/IHC in assessing the CSF of melanoma patients.
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M
elanoma patients with distant metastatic disease
often succumb to the development of metastases
to the CNS (Wasserstrom et al, 1982; de la Monte
et al, 1983; Retsas and Gershuny, 1988; Saha et al,
1994; Meyers and Balch, 1998). Cutaneous
melanoma has a known propensity to frequently metastasize to
the CNS. Brain metastases are identi®ed often (up to 54%) on
routine postmortem examination in advanced stage melanoma
patients (de la Monte et al, 1983; Saha et al, 1994; Meyers and
Balch, 1998). In most cases, the detection of CNS metastases is
associated with a very poor prognosis (Meyers and Balch, 1998).
Presently, the majority of CNS metastases are identi®ed during
routine staging radiographs, or are due to the onset of clinically
signi®cant neurologic symptoms. Both clinically symptomatic and
radiographically detectable lesions usually require metastatic CNS
tumors with a diameter of > 1 cm.
Prolonged survival in patients with limited CNS disease is now
possible with the use of new treatment modalities (Legha et al,
1998; Sampson et al, 1998; Sharpless and das Gupta, 1998; Lavine
et al, 1999; O'Day et al, 1999; Wen and Loef¯er, 1999; Wronski
and Arbit, 2000), although the early identi®cation of patients with
minimal CNS metastatic disease continues to be problematic.
Currently, the CSF is monitored for occult metastatic tumor cells
using standard cytology methods (Bigner, 1992; Bach et al, 1993;
Freilich et al, 1995; Glantz et al, 1998; Straathof et al, 1999);
however, the ef®ciency and sensitivity of CSF cytology is very low,
and thus is of limited clinical utility (Fouladi et al, 1999).
Prior studies by our laboratory, and by others, have demonstrated
that melanoma cells can be detected in body ¯uids using a
multimarker reverse transcriptase-polymerase chain reaction (RT-
PCR) assay, and that this assay can be used to effectively monitor
for the development of subclinical metastasis and tumor progression
(Hoon et al, 1995, 2000; Kuo et al, 1998; Mellado et al, 1999). The
use of a multimarker RT-PCR assay has also been shown to
increase the sensitivity of detecting occult disease as compared with
a single-marker system (Hoon et al, 1995; Sarantou et al, 1997;
Bostick et al, 1999). In this pilot study, we applied a multimarker
melanoma RT-PCR assay to detect occult melanoma cells in the
CSF of AJCC stage IV patients. The main objective of this study
was to determine if RT-PCR analysis of CSF could improve
diagnostic sensitivity over conventional cytology/IHC, using
mRNA markers for tyrosinase, MART-1, and MAGE-3.
MATERIALS AND METHODS
Patient characteristics A total of 37 patients were studied, including
26 males and 11 females with a median age of 43 y (range: 16±83 y).
Five of 37 patients (14%) had metastasis to one organ site, 15 (41%) had
metastases to two sites, and 17 patients (46%) had metastases to three or
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more sites. Five of 37 patients (14%) had a prior history of treated CNS
metastases, including four (11%) with brain metastases and one (3%) with
brain and leptomeningeal metastases.
Specimen collection This study was approved by the institutional
review board at Saint John's Health Center and the John Wayne Cancer
Institute. Specimens of CSF were collected from study patients by
standard lumbar puncture (LP). Thirty-seven patients with stage IV
malignant melanoma underwent an LP to identify melanoma cells in the
CSF using conventional cytologic analysis and RT-PCR. Four of these
patients had MRI evidence of metastases upon entry into the study, and
one additional patient had previously been treated for CNS metastases
with resection followed by gamma knife therapy. Brie¯y, CSF was
obtained, with informed consent, using a standard LP needle inserted at
the posterior L4-5 interspace. After establishing opening pressures, CSF
was collected for a standard chemistry panel, complete cell count. An
additional 2±4 ml of CSF was obtained for standard cytologic
examination to rule out micrometastases. The CSF ¯uid was then
cytospun, air dried, and stained with Wright's stain for cytology analysis
by the pathology department. Cell ®lter and cytospun slides were then
subjected to IHC analysis using anti-S100 and anti-HMB 45 antibodies.
An additional 5 ml of CSF was set aside for RT-PCR analysis.
RNA extraction Total RNA from melanoma cell lines (positive
controls) and peripheral blood lymphocytes (PBL) from healthy
volunteers (negative controls) were extracted using Tri-Reagent
(Molecular Research Center, Cincinnati, OH) as previously described
(Bostick et al, 1999). CSF was ®rst concentrated 10-fold using a
Centricon-10 concentrator (Amicon, Beverly, MA). The CSF
concentrate was then processed using Tri-Reagent LS for liquid samples.
Precipitation of CSF RNA was performed using isopropanol
supplemented with Pellet Paint Co-Precipitant (Novagen, WI).
RT-PCR assay The RT-PCR assay was carried out as previously
described (Bostick et al, 1999). One microgram of RNA was used for all
patient samples in the study, including the control samples. RNA was
incubated at 70°C for 5 min and then put on ice before the addition of
RT reaction reagents. The RNA and added RT reagents were then
incubated at 37°C for 2 h and then at 95°C for 5 min. All RT reactions
were carried out with oligo-dT priming. PCR thermocycling conditions
for tyrosinase, MAGE-3, and MART-1 mRNA detection were set up as
follows: 1 cycle of denaturing at 95°C for 5 min; followed by 35 cycles
of 95°C for 1 min, 55°C for 1 min, and 72°C for 1 min; followed by a
®nal primer sequence extension incubation at 72°C for 10 min. RT-
PCR conditions were set up in a thermocycler (Hybaid, Middlesex,
U.K.). The RT-PCR cDNA products of tyrosinase, MAGE-3, and
MART-1 were then assessed by gel electrophoresis, followed by
Southern blot analysis using speci®c individual marker probes (Bostick et
al, 1999). Detection of the speci®c marker cDNA band by Southern blot
was considered a positive RT-PCR result. Tumor cell lines and tumor
biopsy specimens known to be positive for these markers were included
in the assay as positive RT-PCR controls for each experiment. Negative
controls consisted of reagents without RNA and normal PBL RNA in
each experiment.
RESULTS
Patient characteristics Patients entered into the study with
brain metastases were eligible if they had fewer than ®ve lesions, all
of which were < 1 cm in diameter by magnetic resonance imaging
(MRI). Patients with larger brain lesions were required to undergo
de®nitive therapy with surgery or stereotactic radiosurgery,
followed by a 4-wk period without the development of new
CNS lesions. Pre-study evaluation included a complete history,
physical examination, and routine laboratory tests. Baseline staging
of metastatic disease was assessed by computed tomography (CT)
scans of the chest, abdomen, and pelvis, and MRI of the brain.
Collectively, the study patients demonstrated widely metastatic
disease, with 87% having melanoma metastases disseminated to at
least two organ sites. Four patients with a history of treated brain
metastases, con®rmed radiographically, were entered into this
study. Of these four, one patient had previously undergone
resection, followed by gamma knife radiosurgery treatment for
brain recurrence. No evidence of CNS disease progression was
present on the prestudy MRI in this patient, and the patient
remains alive and free of evaluable CNS disease at this time.
Cytology/IHC and RT-PCR analysis Patients underwent LP
upon accrual into the study and the CSF was collected for cytologic
and IHC analysis, and for RT-PCR. In four of the 37 patients,
suf®cient CSF was not obtainable to allow for IHC analysis.
Conventional cytologic analysis was performed on all 37 patients.
Cytologic analysis identi®ed only one patient of 37 (3%) with
melanoma cells in the CSF. This same patient was the only positive
patient (3%) among 33 patients tested by IHC staining. This patient
was also one of the four patients with MRI evidence of active CNS
metastases upon entry into the study, and expressed all three RT-
PCR markers in the CSF.
RT-PCR analysis of all 37 CSF specimens was performed for
three well-characterized melanoma mRNA markers: tyrosinase,
MAGE-3, and MART-1. Of these 37 patients, eight (22%), eight
(22%), and six (16%) were positive for tyrosinase, MAGE-3, and
MART-1, respectively. Overall, 12 of the 37 (32%) patients were
found to express at least one marker. Five (14%) patients were
positive for one marker, four (11%) patients were positive for two
markers, and three (8%) were positive for three markers. Seven of
37 patients (19%) were RT-PCR positive for two or more markers
(Table I). An additional patient with CSF that was RT-PCR
positive as well as cytologically and IHC negative at the onset of
this study subsequently became both cytologically and IHC positive
6 mo later.
MRI and RT-PCR analysis Of the 37 patients assessed, all
underwent MRI prior to therapy. Of these, only four patients
(11%) were shown to have detectable CNS metastases by MRI at
the onset of this study. Of these four patients, two were RT-PCR
positive. A third MRI-positive patient, who was RT-PCR
negative, had received stereotactic radiosurgery treatment just
prior to CSF analysis.
There were four patients who subsequently developed MRI-
detectable leptomeningeal metastases during treatment. Two of
these four patients were MRI positive for parenchymal CNS
metastases at the start of the study. One of these patients was also
positive by cytology and IHC and by all three RT-PCR markers.
The other MRI-positive patient who later developed lepto-
meningeal disease was RT-PCR negative upon accrual, but a
subsequent CSF specimen was RT-PCR positive 3 mo later. This
Table I. CSF RT-PCR and cytology/IHC analysisa
Number of markers detected
in RT-PCR (+) patient CSF
samples (%)
Number of
patients with
>1 positive
RT-PCR
marker (%)
Number of
cytology and/or
IHC positive
patient CSF
samples (%)b
Number of
MRI (+)
patients (%)
1 2 3
5/37 (14%) 4/37 (11%) 3/37 (8%) 12/37 (32%) 1/37 (3%) 4/37 (11%)
aResults of CSF RT-PCR, CSF cytology/IHC, and brain MRI of 37 patients with AJCC stage IV melanoma.
bFour patients had cytology performed on CSF but not IHC (due to insuf®cient samples).
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patient's ®rst CSF specimen was negative by both cytologic and
RT-PCR analysis, and was also read as ``acellular'' by the
reviewing pathologist. Of the two remaining patients who
developed leptomeningeal metastases but were initially MRI
negative, one was RT-PCR marker positive.
RT-PCR analysis and CNS disease-free prognosis Among
all 37 patients, the simultaneous detection of tyrosinase and
MART-1 in a single patient had the highest level of concordance
(kappa coef®cient = 0.83; p < 0.0001). The predictive value of
MART-1 or/and MAGE-3 marker positivity for the development
of CNS metastasis was signi®cant (p = 0.04; Wald test, multivariate
analysis) at 3 mo.
Overall probability of survival, based on Kaplan-Meier and log
rank analysis (Fig 1), revealed a clear trend towards greater survival
among the 25 patients not expressing melanoma RT-PCR markers
in their CSF as compared with the 12 patients expressing one or
more of these markers, although this trend did not reach statistical
signi®cance (p = 0.07).
DISCUSSION
This study reports the use of RT-PCR analysis of CSF to identify
occult metastatic melanoma cells, and to compare RT-PCR to the
diagnostic ``gold standards'' of cytology/IHC and MRI. The use of
multimarker RT-PCR with speci®c melanoma-associated markers
improves sensitivity over single-marker RT-PCR.
In this study, the overall detection rate of melanoma cells in the
CSF by RT-PCR was 32% compared with only 3% by cytology/
IHC. The accuracy and sensitivity of standard cytologic and IHC
studies of CSF is known to be very poor (Jorda et al, 1998; Fouladi
et al, 1999; Straathof et al, 1999). The ability to accurately identify
occult tumor cells in the CNS by RT-PCR analysis (i.e., prior to
the establishment of radiographically or clinically detectable lesions)
may allow for the application of more speci®c therapies at a more
favorable stage of CNS involvement. This approach would achieve
its greatest value in high risk patients with clinically undetectable
CNS disease. A larger study would be necessary to validate
correlations of CSF RT-PCR positivity with occult CNS disease of
the parenchyma alone versus those patients with leptomeningeal
disease.
Four patients in this study had MRI-documented cerebral
metastases, and two of these were RT-PCR positive. One of these
four patients was positive for cytology, IHC and for all three RT-
PCR markers, and was the only patient of 37 with cytologic
evidence of leptomeningeal spread. Approximately 15±30% of
patients with solid tumor metastases will develop leptomeningeal
metastases (Wasserstrom et al, 1982). Computed tomography alone
is not sensitive enough to con®rm or exclude leptomeningeal
metastases, whereas MRI with gadolinium enhancement is some-
what more sensitive (Fouladi et al, 1999; Straathof et al, 1999; Van
Oostenbrugge and Twijnstra, 1999). Despite its inef®ciency, the
use of standard CSF cytology analysis is still considered one of the
diagnostic procedures of choice. CSF cytology remains a very
insensitive assay despite the multiple CSF samples that are generally
required from an individual patient.
MRI and CT are routinely used to evaluate patients for the
presence of metastatic melanoma to the brain; however, these
studies are limited by their ability to detect lesions < 1 cm. Four of
the patients assessed in this study were MRI positive for CNS
metastases. MRI effectively identi®ed CNS metastases in 11% of
patients, whereas 32% of study patients had positive CSF by
multimarker RT-PCR. A total of 15 of 37 patients (41%) had
either positive MRI and/or positive RT-PCR results. Based upon
the results of this pilot study, the combination of RT-PCR and
MRI together may be more informative than CSF cytology/IHC
and MRI in these patients.
The assessment by RT-PCR of CSF ¯uid appeared to be more
sensitive for CNS disease involvement than either MRI or
cytology. At 4 y following accrual, 23 of 37 patients (62%) have
already developed CNS metastases. Nineteen (51%) had metastates
to the brain, three (8%) had metastases to the brain and
leptomeninges, and one (3%) had leptomeningeal spread. In
assessing the patients who eventually developed CNS metastatic
disease during follow-up, CSF analysis by RT-PCR could detect
approximately 50% of these patients based upon only a single time
point analysis. The monitoring ef®cacy of RT-PCR could
potentially be improved with more CSF samplings at different
stages of treatment. Limitations inherent in such a serial sampling
protocol in patients with subclinical CNS disease include patient
compliance issues and the rare complications associated with
multiple LP. A larger trial incorporating serial CSF samplings for
cytologic and RT-PCR analysis is needed to further validate this
study.
As the multidisciplinary treatment of advanced melanoma
continues to improve, and in particular for patients with visceral
melanoma metastases, more patients are likely to present with CNS
metastases. The longer the duration of metastatic disease in the host,
the greater the potential for melanoma CNS metastases to occur.
The incidence of melanoma CNS metastases is high, and the poor
sensitivity of currently used CSF cytologic studies for early CNS
metastasis is well known. Therefore, new techniques are needed to
improve the sensitivity of detecting subclinical metastasis to the
CNS.
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